Literature DB >> 10752624

Role of residue Y99 in tissue plasminogen activator.

A Vindigni1, M Winfield, Y M Ayala, E Di Cera.   

Abstract

The crystal structure of the fibrinolytic enzyme tissue plasminogen activator (tPA) shows that the bulky side chain of Y99 hinders access to the active site by partially occluding the S2 site and may be responsible for the low catalytic activity of tPA toward plasminogen. We have tested the role of Y99 by replacing it with Leu, the residue found in more proficient proteases like trypsin and thrombin. The Y99L replacement results in an increase in the k(cat)/Km for chromogenic substrates due to enhanced diffusion into the active site. The increase is modest (threefold) for substrates specific for tPA that carry Pro or Gly at P2, but reaches 80-fold for less specific substrates carrying Arg at P2. On the other hand, the Y99L mutation has no effect on the activity of tPA toward the natural substrate plasminogen, that carries Gly at P2, and reduces more than 10-fold the inhibition of tPA by plasminogen activator inhibitor-1 (PAI-1), that carries Ala at P2. We conclude that the steric hindrance provided by Y99 in the crystal structure affects mostly nonphysiological substrates with bulky residues at P2. In addition, residue Y99 plays an active role in the recognition of PAI-1, but not plasminogen. Mutations of Y99 could therefore afford a resistance to inhibition by PAI-1 without compromising the fibrinolytic potency of tPA, a result of potential therapeutic relevance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10752624      PMCID: PMC2144573          DOI: 10.1110/ps.9.3.619

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  21 in total

1.  Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding.

Authors:  K P Hopfner; A Lang; A Karcher; K Sichler; E Kopetzki; H Brandstetter; R Huber; W Bode; R A Engh
Journal:  Structure       Date:  1999-08-15       Impact factor: 5.006

2.  Role of Leu99 of thrombin in determining the P2 specificity of serpins.

Authors:  A R Rezaie
Journal:  Biochemistry       Date:  1997-06-17       Impact factor: 3.162

Review 3.  Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction.

Authors:  R Collins; R Peto; C Baigent; P Sleight
Journal:  N Engl J Med       Date:  1997-03-20       Impact factor: 91.245

Review 4.  New PC versions of the kinetic-simulation and fitting programs, KINSIM and FITSIM.

Authors:  Q Dang; C Frieden
Journal:  Trends Biochem Sci       Date:  1997-08       Impact factor: 13.807

5.  The effect of Arg306-->Ala and Arg506-->Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S.

Authors:  J O Egan; M Kalafatis; K G Mann
Journal:  Protein Sci       Date:  1997-09       Impact factor: 6.725

6.  Release of fibrinopeptides by the slow and fast forms of thrombin.

Authors:  A Vindigni; E Di Cera
Journal:  Biochemistry       Date:  1996-04-09       Impact factor: 3.162

7.  Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

Authors:  M Hoylaerts; D C Rijken; H R Lijnen; D Collen
Journal:  J Biol Chem       Date:  1982-03-25       Impact factor: 5.157

8.  Role of P225 and the C136-C201 disulfide bond in tissue plasminogen activator.

Authors:  A Vindigni; E Di Cera
Journal:  Protein Sci       Date:  1998-08       Impact factor: 6.725

9.  The effect of the one-chain to two-chain conversion in tissue plasminogen activator: characterization of mutations at position 275.

Authors:  D L Higgins; M C Lamb; S L Young; D B Powers; S Anderson
Journal:  Thromb Res       Date:  1990-02-15       Impact factor: 3.944

Review 10.  Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.

Authors:  D Collen; H R Lijnen
Journal:  Thromb Haemost       Date:  1995-07       Impact factor: 5.249

View more
  3 in total

1.  Engineering the substrate and inhibitor specificities of human coagulation Factor VIIa.

Authors:  Katrine S Larsen; Henrik Østergaard; Jais R Bjelke; Ole H Olsen; Hanne B Rasmussen; Leif Christensen; Birthe B Kragelund; Henning R Stennicke
Journal:  Biochem J       Date:  2007-08-01       Impact factor: 3.857

2.  Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1.

Authors:  Lihu Gong; Min Liu; Tu Zeng; Xiaoli Shi; Cai Yuan; Peter A Andreasen; Mingdong Huang
Journal:  J Biol Chem       Date:  2015-08-31       Impact factor: 5.157

3.  Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1.

Authors:  Lihu Gong; Min Liu; Tu Zeng; Xiaoli Shi; Cai Yuan; Peter A Andreasen; Mingdong Huang
Journal:  Data Brief       Date:  2016-01-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.